1-3 of 3
Andrew Mazar, Ph.D.
Close
Sort by
Journal Articles

Evaluation Of Potency and The Associated Biology Of The Investigational Proteasome Inhibitor, Ixazomib: Redox, Autophagic, and MAPK-Dependent Cell Death In T-Cell Lymphoma (TCL) and Hodgkin Lymphoma (HL) Cell Lines and Human Lymphoma Xenograft Models

Ravi Dashnamoorthy, PhD, Irawati Kandela, PhD, Savita Bhalla, PhD, Andrew Mazar, Ph.D., Andrew M Evens, DO, MSc
Journal: Blood
Blood (2013) 122 (21): 4407.
https://doi.org/10.1182/blood.V122.21.4407.4407
Published: 2013
Journal Articles

Darinaparsin in T-Cell Lymphoma (TCL) and Hodgkin Lymphoma (HL) Cells Lines and SCID Xenograft Mouse Models: Single-Agent Activity and Synergistic Cell Death Combined with a PI3K/mTOR Inhibitor

Ravi Dashnamoorthy, Ph.D., Savita Bhalla, PhD, Jennifer Crombie, Irawati Kandela, Ph.D., Andrew Mazar, Ph.D., Andrew M. Evens, DO, MSc
Journal: Blood
Blood (2012) 120 (21): 1646.
https://doi.org/10.1182/blood.V120.21.1646.1646
Published: 2012
Journal Articles

The 2 nd Generation Proteasome Inhibitor, MLN2238: Potent Induction of Cell Death in T-Cell Lymphoma (TCL) and Hodgkin Lymphoma (HL) Cell Lines and in Two Human Lymphoma Xenograft Models.

Ravi Dashnamoorthy, Ph.D., Irawati Kandela, Ph.D., Savita Bhalla, PhD, Jasmine Galloway, Irina Zaretsky, Andrew Mazar, Ph.D., Andrew M. Evens, DO, MSc
Journal: Blood
Blood (2012) 120 (21): 2767.
https://doi.org/10.1182/blood.V120.21.2767.2767
Published: 2012